Arcus Biosciences, Inc. RCUS
Set alert
At close · Oct 30
After hours · Oct 30, 4:01 PM ET
- YTD
- -23.67%
- 1 year
- -9.91%
- Open
- 18.34
- Prev close
- 18.61
- Mkt cap
- 2.32B
- Vol
- 1.94M
- Avg vol
- 1.80M
- EPS
- -3.91
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 17.82
- High
- 18.90
- Forward P/E
- -5.84
- Beta
- 0.94
- Short ratio
- 8.16
- Inst. own
- 66.38%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 25.20
- 200-d avg
- 24.70
- 1y target
- 41.00
News
5 days ago businesswire.com
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for…
1 week ago gurufocus.com
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the tr
1 week ago businesswire.com
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the…
1 week ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics…
-
1 week ago benzinga.com
Arcus Biosciences Commences Public Offering of Common Stock; Size Not Disclosed
Arcus Biosciences, Inc. (NYSE:RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune…
1 week ago prnewswire.com
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Arcus Biosciences, Inc. ( NYSE : RCUS) breached…
1 week ago businesswire.com
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for…
-
1 week ago benzinga.com
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50
Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $45 to $50.
-
1 week ago benzinga.com
Truist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41
Truist Securities analyst Supawat Thongthip maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $40 to $41.
-
1 week ago benzinga.com
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $49
Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $43 to $49.
1 week ago seekingalpha.com
Arcus Biosciences: Encouraging Casdatifan Data, But The Hard Part Still Ahead
Arcus Biosciences presented promising ARC-20 platform data for casdatifan across first-line, second-line, and late-line clear cell renal cell carcinoma settings. RCUS's casdatifan combinations showed…
1 week ago marketbeat.com
Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Day
Arcus Biosciences NYSE: RCUS presented updated clinical and translational data for casdatifan, its investigational HIF-2 alpha inhibitor, outlining development plans across first-line, second-line…
1 week ago seekingalpha.com
Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy Transcript
Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy Transcript
1 week ago zacks.com
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-
1 week ago benzinga.com
Arcus Biosciences Reports Casdatifan Kidney Cancer Data, With Nearly 3-Year Median Overall Survival In Heavily Pretreated Patients And Phase 3 Trials Remain Pending
Progression-free survival (PFS) for casdatifan plus anti-PD-1 in the first-line (1L) setting exceeded third-party benchmarks* for the approved anti-PD-1 plus anti-CTLA-4 regimen (ipilimumab plus…
1 week ago businesswire.com
Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for…
-
2 weeks ago benzinga.com
William Blair Initiates Coverage On Arcus Biosciences with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Outperform rating.
-
2 weeks ago benzinga.com
JP Morgan Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $41
JP Morgan analyst Priyanka Grover initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Overweight rating and announces Price Target of $41.
3 weeks ago businesswire.com
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for…
-
1 month ago benzinga.com
Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target
Wedbush analyst Robert Driscoll reiterates Arcus Biosciences (NYSE:RCUS) with a Outperform and maintains $43 price target.
1 month ago businesswire.com
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for…
1 month ago businesswire.com
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for…
1 month ago seekingalpha.com
Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics…
1 month ago businesswire.com
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for…
1 month ago seekingalpha.com
Arcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Arcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
-
1 month ago benzinga.com
Truist Securities Reiterates Buy on Arcus Biosciences, Raises Price Target to $40
Truist Securities analyst Supawat Thongthip reiterates Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $35 to $40.
2 months ago businesswire.com
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people…
2 months ago defenseworld.net
BlackRock Inc. Makes New $506.11 Million Investment in Arcus Biosciences, Inc. $RCUS
BlackRock Inc. bought a new stake in Arcus Biosciences, Inc. (NYSE: RCUS) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission.…
2 months ago prnewswire.com
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Arcus Biosciences, Inc. ( NYSE : RCUS) breached…
2 months ago businesswire.com
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for…
-
2 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26
Wells Fargo analyst Eva Fortea Verdejo maintains Arcus Biosciences (NYSE:RCUS) with a Equal-Weight and raises the price target from $23 to $26.
-
2 months ago benzinga.com
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $43
Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $41 to $43.
-
2 months ago benzinga.com
Arcus Biosciences Q2 EPS $(0.72) Beats $(0.87) Estimate, Sales $41.000M Beat $23.405M Estimate
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.87) by 17.24 percent. This is a Infinity percent decrease over earnings…
-
3 months ago benzinga.com
Arcus Biosciences Announces A Clinical Supply Agreement With AVEO Oncology To Evaluate Casdatifan; Agreement Supports A New Randomized Cohort Within The ARC-20 Study Evaluating Investigational Casdatifan Plus Tivozanib Versus Tivozanib Alone In Patients Who Received Prior HIF-2α-inhibitor Therapy; Enrollment Expected To Begin In Q4 2026
This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor…
-
3 months ago benzinga.com
Arcus Biosciences And Summit Therapeutics Announced A Clinical Trial Collaboration To Evaluate The Safety And Efficacy Of Arcus’s Casdatifan; Data Expected to Be Generated By Mid-2027
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and…
3 months ago benzinga.com
Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?
HC Wainwright lifted Arcus Biosciences' price target, citing broader revenue potential for casdatifan in first-line ccRCC.
-
3 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $45
HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $32 to $45.
-
4 months ago benzinga.com
Arcus Biosciences Announces Publication In Nature Describing New Research From The ARC-20 Study Showing Casdatifan HIF-2a Inhibition Deeply Suppresses Serum EPO And Extends Progression-Free Survival In Advanced Kidney Cancer
This is the first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor with peripheral biomarker changes and associated tumor biologyHIF-2a inhibition…
-
5 months ago benzinga.com
Arcus Biosciences Enters Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb; Will Supply Casdatifan, Its Investigational Small-Molecule HIF-2a Inhibitor
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and…
-
5 months ago benzinga.com
Truist Securities Assumes Arcus Biosciences at Buy, Raises Price Target to $35
Truist Securities analyst Supawat Thongthip assumes Arcus Biosciences (NYSE:RCUS) with a Buy rating and raises Price Target to $35.
-
5 months ago benzinga.com
Morgan Stanley Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $22
Morgan Stanley analyst Terence Flynn maintains Arcus Biosciences (NYSE:RCUS) with a Equal-Weight and raises the price target from $20 to $22.
-
5 months ago benzinga.com
Goldman Sachs Maintains Buy on Arcus Biosciences, Raises Price Target to $34
Goldman Sachs analyst Richard Law maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $30 to $34.
-
5 months ago benzinga.com
Arcus Biosciences Q1 EPS $(1.02) Misses $(0.93) Estimate, Sales $17.000M Miss $29.484M Estimate
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.02) per share which missed the analyst consensus estimate of $(0.93) by 9.68 percent. This is a 10.53 percent increase over losses of…
6 months ago benzinga.com
What's Going On With Arcus Biosciences Stock On Wednesday?
Arcus Biosciences halts STAR-121 lung cancer trial after futility review while Gilead Science declines option extension.
-
8 months ago benzinga.com
Earnings Scheduled For February 25, 2026
Earnings Scheduled For February 25, 2026
11 months ago benzinga.com
Semtech Posts Mixed Q3 Results, Joins Zhihu, Nvidia And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Semtech Posts Mixed Q3 Results, Joins Zhihu, Nvidia And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
11 months ago benzinga.com
Why Keysight Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Why Keysight Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
11 months ago benzinga.com
The Insider Report: Prepare for the Next Dip Buying Opportunity
The Insider Report: Prepare for the Next Dip Buying Opportunity